title: Sequential single-agent obatoclax mesylate (GX15-070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma.
authors.affiliation: John Theurer Cancer Center, Hackensack University Medical Center , Hackensack, NJ , USA.
authors.forename: André
authors.initials: A
authors.lastname: Goy
authors.forename: Mark
authors.initials: M
authors.lastname: Berger
authors.forename: Peggy
authors.initials: P
authors.lastname: Ford
authors.forename: Tatyana
authors.initials: T
authors.lastname: Feldman
authors.forename: Anthony
authors.initials: A
authors.lastname: Mato
authors.forename: Colleen
authors.initials: C
authors.lastname: Bejot
authors.forename: Henry C
authors.initials: HC
authors.lastname: Fung
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D007211:Indoles; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D011758:Pyrroles / Q000008:administration & dosage; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007211:Indoles; D011758:Pyrroles; D000069283:Rituximab; C520962:obatoclax